NEUROCRINE BIOSCIENCES | 5,160 Euro | +0,053 +1,04 % | |
| WKN: 900964 ISIN: US64125C1099 Ticker-Symbol: NB3 | Frankfurt | 28.05.12 | 08:05 Uhr |
Branche BiotechnologieAktienmarkt NASDAQ Biotech |
|
| Zeit | Aktuelle Nachrichten | Leser | Medien | |
|---|---|---|---|---|
| 17.05. | Neurocrine Biosciences Announces Urocortin 2 Phase II Study Results in Patients With Acute Decompensated Heart Failure; Drug Generally Well Tolerated | 1 | Benzinga.com | |
| 17.05. | Neurocrine Biosciences Announces Urocortin 2 Phase II Study Results in Patients With Acute Decompensated Heart Failure | 15 | PR Newswire | |
| SAN DIEGO, May 17, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced efficacy and safety results from a Phase II trial of urocortin 2 in 53 patients with acute decompensated... Mehr lesen zu: Neurocrine Biosciences Announces Urocortin 2 Phase II Study Results in Patients With Acute Decompensated Heart Failure | ||||
| 09.05. | Neurocrine Biosciences' CEO Presents at Deutsche Bank 37th Annual Health Care Conference (Transcript) | 5 | Seeking Alpha | |
| 04.05. | Neurocrine Biosciences To Present At The Deutsche Bank 37th Annual Health Care Conference | 45 | PR Newswire | |
| SAN DIEGO, May 4, 2012 /PRNewswire/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting... Mehr lesen zu: Neurocrine Biosciences To Present At The Deutsche Bank 37th Annual Health Care Conference | ||||
| 03.05. | Neurocrine Biosciences' CEO Discusses Q1 2012 Results - Earnings Call Transcript | 1 | Seeking Alpha | |
| 02.05. | Neurocrine Biosciences Reports First Quarter 2012 Results | 23 | PR Newswire | |
| SAN DIEGO, May 2, 2012 /PRNewswire/ --Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended March 31, 2012. For the first quarter of 2012, the Company... Mehr lesen zu: Neurocrine Biosciences Reports First Quarter 2012 Results | ||||
| 01.05. | Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results | 9 | PR Newswire | |
| SAN DIEGO, April 25, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2012 financial results after... Mehr lesen zu: Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results | ||||
| 25.04. | Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results | 24 | PR Newswire | |
| SAN DIEGO, April 25, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its first quarter 2012 financial results after... Mehr lesen zu: Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results | ||||
| 27.03. | Neurocrine Biosciences to Present at the 11th Annual Needham Healthcare Conference | 36 | PR Newswire | |
| SAN DIEGO, March 27, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences... Mehr lesen zu: Neurocrine Biosciences to Present at the 11th Annual Needham Healthcare Conference | ||||
| 27.03. | Neurocrine Says Elagolix Endometriosis Phase III Trials On Track To Begin In Q2 | 49 | AFX News | |
| WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc. (NBIX) announced that
comments from the United States Food and Drug Administration are not expected to
have an impact on the start of the... Mehr lesen zu: Neurocrine Says Elagolix Endometriosis Phase III Trials On Track To Begin In Q2 | ||||
| 26.03. | Neurocrine's Tardive Dyskinesia Drug Study Fails Primary Endpoints | 55 | AFX News | |
| WASHINGTON (dpa-AFX) - Neurocrine Biosciences, Inc. (NBIX) said Monday a
Phase II trial of NBI-98854 did not meet primary endpoints of efficacy, due
mainly to the inclusion of an inconsistent... Mehr lesen zu: Neurocrine's Tardive Dyskinesia Drug Study Fails Primary Endpoints | ||||
| 26.03. | Neurocrine (NBIX) Reports Notable Safety Results from NBI-98854 Phase II | 2 | StreetInsider.com | |
| 26.03. | Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia | 28 | PR Newswire | |
| SAN DIEGO, March 26, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced efficacy and safety results from a Phase II trial of NBI-98854 in 37 tardive dyskinesia patients.... Mehr lesen zu: Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia | ||||
| 16.03. | Neurocrine Biosciences wird von der Deutschen Bank mit Buy Rating und Kursz... | 113 | BörseGo | |
| Neurocrine Biosciences wird von der Deutschen Bank mit Buy Rating und Kursziel $15,00 aufgenommen
(© BörseGo AG 2012 - Autor: Christian Hoyer, Redakteur) Mehr lesen zu: Neurocrine Biosciences wird von der Deutschen Bank mit Buy Rating und Kursz... | ||||
| 16.03. | Deutsche Bank startet Neurocrine Biosci mit Buy. | 37 | BörseGo | |
| Deutsche Bank startet Neurocrine Biosci mit Buy.
(© BörseGo AG 2012 - Autor: Thomas Gansneder, Redakteur) Mehr lesen zu: Deutsche Bank startet Neurocrine Biosci mit Buy. | ||||
| 07.03. | Neurocrine Biosciences to Present at The 24th Annual Roth Conference | 27 | PR Newswire | |
| SAN DIEGO, March 7, 2012 /PRNewswire/ --Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Vice President and Chief Financial Officer of Neurocrine Biosciences... Mehr lesen zu: Neurocrine Biosciences to Present at The 24th Annual Roth Conference | ||||
| 29.02. | Neurocrine Biosciences to Present at the 32nd Annual Cowen Health Care Conference | 28 | PR Newswire | |
| SAN DIEGO, Feb. 29, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences... Mehr lesen zu: Neurocrine Biosciences to Present at the 32nd Annual Cowen Health Care Conference | ||||
| 21.02. | Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference | 27 | PR Newswire | |
| SAN DIEGO, Feb.21, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences... Mehr lesen zu: Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference | ||||
| 15.02. | A Walk Through Neurocrine Biosciences | 45 | AFX News | |
| WASHINGTON (dpa-AFX) - Shares of Neurocrine Biosciences Inc. (NBIX) have
been up 60 percent since hitting a low for the year in early October, and trade
around $8.60. This biopharmaceutical... Mehr lesen zu: A Walk Through Neurocrine Biosciences | ||||
| 09.02. | NEUROCRINE BIOSCIENCES INC - 10-K, Annual Report | 1 | SEC Filings | |
Startseite • Nachrichten • Aktienkurse • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Chartanalysen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage
